Daniel Zelterman



2462 Windham Hill Rd
PO Box 1115
W Townshend, VT 05359

daniel.zelterman@yale.edu

203–859–8836 (cell)

Education

Ph.D.	1983	Statistics, Yale University
B.A.	1975	Mathematics
B.A.		Statistics, and Computer Science State University of New York at Buffalo

Academic Experience

1995–present	Professor, Department of Biostatistics Epidemiology and Public Health, Yale University Acting Department Head (Jan. – July, 2005) Emeritus, July, 2020
1988–95	Assistant Professor/Associate Professor Division of Biostatistics, School of Public Health University of Minnesota, Minneapolis
1980–90	Lecturer/Assistant Professor/Associate Professor Department of Mathematics and Statistics State University of New York at Albany

October 8, 2026

Books

1. D Zelterman (1999). *Models for Discrete Data*, Oxford University Press. ix + 232pp ISBN: 0–19–852436–6

2. D Zelterman (2002). *Advanced Log-Linear Models Using SAS*, Cary, N.C.: SAS Institute. ix + 189pp

3. D Zelterman (2005). *Discrete Distributions: Application in the Health Sciences*, New York: J. Wiley. xix + 277pp ISBN: 978-0-470-86889-8

4. D Zelterman (2006). *Models for Discrete Data*, Revised Edition, Oxford University Press. x + 285pp ISBN 9780198567011

5. D Zelterman (2010). *Applied Linear Models with SAS,* Cambridge University Press. ISBN 978–0–521–76159–8. xiv + 273pp

6. D Zelterman (2015). *Applied Multivariate Statistics with R.* Springer. ISSN 1431–8776. xvi + 393.

7. D Zelterman (2022). *Regression for Health and Social Science: Applied Linear Models with R*, Cambridge University Press. ISSN 978–1–108–47818–2.

8. D Zelterman (2022). *Applied Multivariate Statistics with R.* Springer. 2nd Edition Springer. xix+463pp ISBN 978–3–031–13004–5.

Awards

Fellow, American Statistical Association – 1998.

Selected Editorial Boards

Biometrics, Associate Editor.
Computational Statistics & Data Analysis, Associate Editor
Journal of Agricultural, Biological and Environmental Statistics, Associate Editor
Journal of Statistical Theory and Practice, Associate Editor

Recent Service and Consultations

Science Advisory Panel to the US EPA (Federal Insecticide, Fungicide, and Rodenticide Act):

Carcinogenicity of ethylene oxide (Nov. 2014).

Carcinogenicity of Glyphosphate (Dec. 2016).

Advisory Committee to the US FDA/CDER: Divisions: Anesthetic and Analgesic Drug Products; Life Support Drugs; Pulmonary, Allergy, and Rheumatology Products. (2005–2014).

Wilks Memorial Medal, Selection Committee (2006–11), Chair (2008–10).

Recent Data Safety Monitoring Boards

Abliva: An interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose, adaptive study of the efficacy of KL1333 in adult patients with primary mitochondrial disease (KL1333 2020-104A) 2022.

Savara: A randomized, double-blind, placebo-controlled clinical trial of once-daily inhaled molgramostim nebulizer solution in adult subjects with autoimmune pulmonary alveolar proteinosis (aPAP) (SAV006–05) 2020.

Bristol-Myers Squibb: Study of Nivolumab in patients With classical Hodgkin's Lymphoma (Registrational) (CheckMate 205) 2018.

Bristol-Myers Squibb: Prevention of central venous catheter-associated thrombosis in critically ill children: A multicenter phase 2a trial. (NCT03003390) 2017.

Bristol-Myers Squibb: A study of Nivolumab plus Brentuximab Vedotin in patients between 5 and 30 years old, With Hodgkin's Lymphoma (cHL), relapsed or refractory from first line treatment (CheckMate 744) 2016.

Bristol-Myers Squibb: A phase 1b, open-label, multicenter study of (BMS-936564) in combination with Lenalidomide (Revlimid) plus low-dose Dexamethasone, or with Bortezomib (Velcade) plus Dexamethasone in subjects with relapsed or refractory multiple myeloma. 2011

Refereed Publications – Theory and Methodology

1. Zelterman D. (1984). Approximating the distribution of goodness of fit tests for discrete data. *Computational Statistics and Data Analysis* **2**: 207–14.

2. Zelterman D. (1986). The log likelihood ratio for sparse multinomial mixtures. *Statistics & Probability Letters* **4**: 95–9.

3. Zelterman D. (1987). Goodness–of–fit tests for large sparse multinomial distributions. *Journal of the American Statistical Association* **82**: 624–9.

4. Zelterman D. (1987). Estimating percentage points by simulation. *Journal of Statistical Computation and Simulation* **27**: 107–25.

5. Zelterman D. (1987). Parameter estimation in the generalized logistic distribution. *Computational Statistics and Data Analysis* **5**: 177–84.

6. Zelterman D. (1988). Likelihood ratio tests for central mixtures. *Statistics & Probability Letters* **6**: 275–9.

7. Zelterman D. (1988). Robust estimation in truncated discrete distributions with application to capture-recapture experiments. *Journal of Statistical Planning and Inference* **18**: 225–37.

8. Zelterman D and Chen C-F. (1988). Homogeneity tests against central mixture alternatives. *Journal of the American Statistical Association* **83**: 179–82.

9. Zelterman D. (1989). Testing for central mixtures of compartment model parameters. *Statistics in Medicine* **8**: 1011–21. PMID: 2799120

10. Zelterman D. (1989). Order statistics of the generalized logistic distribution. *Computational Statistics and Data Analysis* **7**: 69–77.

11. Zelterman D. (1990). On tests for qualitative interactions. *Statistics & Probability Letters* **10**: 59–63.

12. Zelterman D. (1990). Smooth nonparametric estimation of the quantile function. *Journal of Statistical Planning and Inference* **26**: 339–52.

13. Le CT, Lindgren BR, Zelterman D and Umen AJ. (1991). Homogeneity of the relative risk in cohort studies. *Statistics in Medicine* **10**: 1267–72. PMID 1925157

14. Zelterman D and Le CT. (1991). Tests of homogeneity for the relative risk in multiply–matched case–control studies. *Biometrics* **47**: 751–6. PMID: 1912269

Refereed Publications – Theory and Methodology

15. Zelterman D. (1992). A statistical distribution with an unbounded hazard function and its application to a theory from demography. *Biometrics* **48**: 807–18. PMID: 1420843

16. Zelterman D and Youn TIK. (1992). Indicator models in social mobility tables. *Computational Statistics & Data Analysis* **14**: 39–53.

17. Le CT and Zelterman D. (1992). Goodness of fit tests for proportional hazards regression models. *Biometrical Journal* **34**: 557–66.

18. Devidas N, George EO and Zelterman D. (1993). Generalized logistic models for low–dose response data. *Statistics in Medicine* **12**: 881–92. PMID: 8327804

19. Le CT, Grambsch PM, Zelterman D and Lindgren B. (1993). Evaluation of staging systems for colorectal cancer. *Biometrical Journal* **35**: 701–5. PMID: 8204986

20. Zelterman D. (1993). A semiparametric bootstrap technique for simulating extreme order statistics. *Journal of the American Statistical Association* **88**: 477–85.

21. Mielke PW, Berry KJ and Zelterman D. (1994). Fisher's exact test of mutual independence for $2 \times 2 \times 2$ cross-classification tables. *Educational and Psychological Measurement* **54**: 110–4.

22. Zelterman D, Grambsch PM, Le CT, Ma JZ, Curtsinger JW. (1994). Piecewise exponential survival curves with smooth transitions. *Mathematical Biosciences* **120**: 233–50. PMID: 8204986

23. Zelterman D and Curtsinger JW. (1995). Survival curves subjected to occasional insults. *Biometrics* **51**: 1140–6. PMID: 7548697

24. Zelterman D, Chan SF and Mielke PW. (1995). Exact tests of significance in higher dimensional tables. *The American Statistician* **49**: 357–61.

25. Zelterman D, Le CT and Louis TA. (1996). Bootstrap techniques for proportional hazards models with censored observations. *Statistics and Computing* **6**: 191–9.

26. Waller LA and Zelterman D. (1997). Log-linear modeling with the negative multinomial distribution. *Biometrics* **53**: 971–82.

27. Yu C, Waller LA and Zelterman D. (1998). Discrete distributions for use in twin studies. *Biometrics* **54**: 546–57.

Refereed Publications – Theory and Methodology

28. Nadkarni PM, Brandt C, Frawley S, Sayward FG, Einbinder R, Zelterman D, Schacter L, Miller PL. (1998). Managing attribute-value clinical trials data using the ACT/DB client-server database system. *Journal of the American Medical Informatics Association* **5**: 139–51.

29. Zhang H and Zelterman D. (1999). Binary regression for risks in excess of subject specific threshholds. *Biometrics* **55**: 1247–51.

30. Zelterman D, LaMotte R and Friedman R. (2000). Models for discrete circular orientation. *Far East Journal of Theoretical Statistics* **4**: 13–25.

31. Zhang Z, Burtness BA and Zelterman D. (2000). The maximum negative binomial distribution. *Journal of Statistical Planning and Inference* **87**: 1–19.

32. Yu C and Zelterman D. (2001). Exact inference for family disease clusters. *Communications in Statistics: Theory and Methods* **30**: 2293–305.

33. Li J and Zelterman D. (2002). Rank tests for exchangeable paired data. *Computational Statistics & Data Analysis* **40**: 111–29.

34. Yu C and Zelterman D. (2002). Sums of dependent Bernoulli random variables and disease clustering. *Statistics & Probability Letters* **57**: 363–73.

35. Yu C and Zelterman D. (2002). Statistical inference for family disease clusters. *Biometrics* **58**: 481–91. UI: 12229982

36. Li Y, Zelterman D, and Forsyth BWC. (2003). Analyzing multiply matched cohort studies with two different comparison groups: Application to pregnancy rates among HIV+ women. *Biometrics* **59**: 632–9. UI: 14601764

37. Zelterman D. (2006). An occupancy distribution arising in a limiting dilution assay for HIV-1. *Statistics & Probability Letters* **76**: 1–9.

38. Nandram B, Zelterman D. (2007). Computational Bayesian inference for estimating the size of a finite population. *Computational Statistics & Data Analysis* **51**: 2934–45.

39. Yu C, Zelterman, D. (2007). Sums of exchangeable Bernoulli random variables for family and litter frequency data. *Computational Statistics & Data Analysis* **52**: 1636-1649.

40. Gueorguieva R, Rosenheck R, Zelterman D. (2008). Dirichlet component regression and its applications to psychiatric data. *Computational Statistics & Data Analysis* **52**: 5344–5355.

Refereed Publications – Theory and Methodology

41. Zelterman D, Tulupyev A, Heimer R, Abdala N (2010). Statistical design for a small serial dilution series. *Statistics in Medicine* **29**: 411–20. doi: 10.1002/sim.3774.

42. Tulupyev A, Suvorova A, Sousa J, Zelterman D (2013). Beta prime regression with application to risky behavior frequency screening. *Statistics in Medicine* **32**:4044–4056. doi: 10.1002/sim.5820.

43. Ryslik GA, Cheng Y, Cheung K-H, Bjornson RD, Zelterman D, Modis Y,Zhao H (2014). A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. *BMC Bioinformatics*, **15**:231. doi:10.1186/1471-2105-15-231

44. Crawford F, Zelterman D. (2015). Markov counting models for correlated binary responses. *Biostatistics* **16**:427–440. doi:10.1093/biostatistics/kxv006

45. Yu C and Zelterman D (2017). A general approximation to quantiles. *Communications in Statistics*–Theory and Methods. **46**:9834–9841 doi: 10.1080/03610926.2016.1222433

46. Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. (2017). Testing violations of exponential assumption in cancer clinical trials with survival endpoints. *Biometrics* **73**:687–695. doi: 10.1111/biom.12590

47. Yu C and Zelterman D. (2017). A parametric model to estimate the proportion from true null using a distribution for p-values. *Computational Statistics & Data Analysis* **114**:105–18. doi: 10.1016/j.csda.2017.04.008

48. DeVeaux M, Kane M, Zelterman D. (2018). Clinical trial design using a stopped negative binomial distribution. *Statistics and Its Interface* **11**: 699–707. doi: 10.4310/SII.2018.v11.n4.a13.

49. Yu C and Zelterman D. (2019). A parametric meta–analysis. *Statistics in Medicine*. **38**:4013–4025. doi: 10.1002/sim.8278

50. DeVeaux M, Kane M, Wei W, Zelterman D. (2019). A two-stage, Phase II clinical trial design with nested criteria for early stopping and efficacy *Pharmaceutical Statistics* doi: 10.1002/pst.1965

51. Crump K, Crouch E, Zelterman D, Crump C, Haseman J (2020). Accounting for multiple comparisons in statistical analysis of the extensive bioassay data on Glyphosate. *Toxicological Sciences* **175**:156-167. doi: 10.1093/toxsci/kfaa039

Refereed Publications – Theory and Methodology

52. Yu C, Zelterman D. (2020). Distributions associated with simultaneous multiple hypothesis testing. *Journal of Statistical Distributions and Applications* **7:9**

    doi: 10.1186/s40488-020-00109-6

53. Crump K, Crouch E, Zelterman D, Crump C, Haseman J (2020). Correcting for multiple comparisons in statistical analysis of animal bioassay data. *Toxicological Sciences* **177**:523–524. doi: 10.1093/toxsci/kfaa078

54. Wei W, Esserman D, Kane M, Zelterman D (2021). Unified exact design with early stopping rules for single arm clinical trials with multiple endpoints. *Statistical Methods in Medical Research* **30**:1575–1588 doi: 10.1177/09622802211013062

55. Liu Y, Kane M, Esserman D, Blaha O, Zelterman D, Wei W. (2022). Bayesian local exchangeability design for phase II basket trials. *Statistics in Medicine* **41**:4367-4384. doi: 10.1002/sim.9514.

56. Yu C, Blaha O, Kane M, Wei W, Esserman D, Zelterman D (2022). Regression methods for the appearances of extremes in climate data. *Environmetrics* **33** doi: 10.1002/env.2764

57. Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J (2024). A Bayesian platform trial design with hybrid control based on multisource exchangeability modeling. *Statistics in Medicine* **43**(12): 2439-2451. doi: 10.1002/sim.10077

58. Yu C, Kane M, Blaha O, Wei W, Esserman D, Zelterman D (2026). A joint distribution for indexes of extremes with applications to climate change. *Statistics and its Interface* **19**: 197-209. doi: 10.4310/SII.260108021930

59. Yu C, Wei W, Zelterman D (2026). Change-point homogeneity in piecewise exponential survival *Journal of Statistical Theory and Practice* **20** doi: 10.1007/s42519-026-00551-w

Refereed Publications – Applications

60. Shaywitz BA, Gordon JW, Klopper JH, Zelterman D (1977). The effect of 6-hydroxydopamine on the habituation of activity in the developing rat pup. *Pharmacology, Biochemistry, and Behavior* **6**: 391–6.

61. Shaywitz BA, Gordon JW, Klopper JH, Zelterman D, Irvine J (1979). Ontogenesis of spontaneous activity and habituation of activity in the rat pup. *Developmental Psychobiology* **12**: 359–67.

62. Bennett JA, Gruft H, McKneally M, Zelterman D, Crispen RG (1983). Differences in biological activity among batches of lyophilized Tice *Bacillus Calmette-Guérin* and their association with clinical course in Stage I lung cancer. *Cancer Research* **43**: 4183–90.

63. Okagaki T and Zelterman D (1990). Information, discrimination and divergence in cytology: I. Theoretical aspects and definitions. *Analytical and Quantitative Cytology and Histology* **12**: 342–7.

64. Okagaki T and Zelterman D (1991). Information, discrimination and divergence in cytology: II. Total discrimination as a measure of performance. *Acta Cytologica* **35**: 25–9.

65. Okagaki T, Fujimura M, Zelterman D (1991). Information, discrimination and divergence in cytology: III. Optimization of classification of Papanicolaou smears. *Acta Cytologica* **35**: 30–4.

66. Okagaki T, Fujimura M, Brooker DC, McIntosh L, Zelterman D (1991). Information, discrimination and divergence in cytology: IV. Quality control of diagnostic cytology. *Acta Cytologica* **35**: 35–9.

67. Nonomura N, Giebink GS, Zelterman D, Harada T, Juhn SK (1991). Early biochemical events in pneumococcal otitis media: Kinetics of arachidonic acid metabolism. *Annals of Otology, Rhinology, and Laryngology* **100**: 385–8.

68. Ruah CB, Schachern PA, Zelterman D, Paparella MM, Yoon TH (1991). Age-related morphologic changes in the human tympanic membrane. *Archives of Otorhinolaryngology – Head and Neck Surgery* **117**: 627–34.

69. Garrard J, Makris L, Dunham T, Heston LL, Cooper S, Ratner ER, Zelterman D, Kane RL (1991). Evaluation of neuroleptic drug use by nursing home elderly under proposed Medicare and Medicaid regulations. *Journal of the American Medical Association* (and its Japanese translation) **265**: 463–7.

Refereed Publications – Applications

70. Nonomura N, Giebink SG, Zelterman D, Harada T, Juhn SK. (1991). Middle ear fluid lysozyme source in experimental pneumoccal otitis media. *Annals of Otology, Rhinology, and Laryngology* **100**: 593–6.

71. Okagaki T, Lau M, Zelterman D. (1992). Information, discrimination and divergence in cytology VI. Biases and errors of measurements in small samples. *Analytical and Quantitative Cytology and Histology* **14**: 238–44.

72. Heston LL, Garrard J, Makris L, Kane RL, Cooper S, Dunham T, Zelterman D. (1992). Inadequate treatment of depressed nursing home elderly. *Journal of the American Geriatrics Society* **40**: 1117–22.

73. Garrard J, Dunham T, Makris L, Cooper S, Heston LL, Ratner ER, Zelterman D, Kane RL. (1992). Longitudinal study of psychotropic drug use by nursing home elderly. *Journal of Gerontology: Medical Sciences* **47**: M183–8.

74. Okagaki T, Lau M, Brooker DC, Zelterman D. (1992). Morphologic scales and relative distances between lesions identified by Papanicolaou smears. *Analytical and Quantitative Cytology and Histology* **14**: 335–40.

75. Ruah CB, Schachern PA, Paparella MM, Zelterman D. (1992). Mechanisms of retraction pocket formation in the pediatric tympanic membrane. *Archives of Otolaryngology - Head and Neck Surgery* **118**: 1298–305.

76. Kirby D, Resnick MD, Downes B, Kocher T, Gunderson P, Potthoff S, Zelterman D, Blum RW. (1993). The effects of school–based health clinics in St. Paul upon school–wide birth rates. *Family Planning Perspectives* **25**: 12–6.

77. Sperling NM, Paparella MM, Yoon TH, Zelterman D. (1993). Symptomatic versus asymptomatic endolymphatic hydrops: A histopathologic comparison. *Laryngoscope* **103**: 277–85.

78. Ostrow RS, Coughlin S, McGlennen RC, Liu Z, Zelterman D, Faras AJ. (1994). Topical CTC-96 accelerates wart growth in rabbits infected with cottontail rabbit papillomavirus. *Antiviral Research* **24**: 27–35.

79. Moreano EH, Paparella MM, Zelterman D, Goycoolea MV. (1994). Prevalence of facial canal dehiscence and of persistent stapedial artery in the human middle ear: A report of 1000 temporal bones. *Laryngoscope* **104**: 309–20.

Refereed Publications – Applications

80. Moreano EH, Paparella MM, Zelterman D, Goycoolea MV. (1994). Prevalence of carotid canal dehiscence in the human middle ear: A report of 1000 temporal bones. *Laryngoscope* **104**: 612–8.

81. Moreano EH, Paparella MM, Zelterman D, Goycoolea MV. (1994). Prevalence of microfissures in the human temporal bone: A report of 1000 temporal bones. *Laryngoscope* **104**: 741–6.

82. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Keil RK, Cardinale J, Cooper DL. (1996). Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. *Journal of Clinical Oncology* **14**: 2435–43.

83. Ramphal-Naley L, Kirkhorn S, Lohman WH, Zelterman D. (1996). Tuberculosis in physicians: Compliance with surveillance and treatment. *American Journal of Infection Control* **24**: 243–53.

84. Salloum E, Brandt DS, Caride VJ, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper DL. (1997). Gallium scans in the management of patients with Hodgkin's disease: A study of 101 cases. *Journal of Clinical Oncology* **15**: 518–27.

85. Modlin IM, Sandor A, Tang LH, Kidd M, Zelterman D. (1997). A 40-year analysis of 265 gastric carcinoids. *American Journal of Gastroenterology* **92**: 633–38.

86. Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. (1997). Dose–escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. *Journal of Clinical Oncology* **15**: 148–57.

87. Salloum E, Jillella AP, Nadkarni R, Seropian S, Hu GL, D'Andrea E, Zelterman D, Cooper DL. (1998). Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. *Cancer* **82**: 1506–12.

88. Murren JR, Gollerkeri A, Anderson S, Lutzker S, Del Prete S, Zelterman D, Garrison L, Smith B. (1998). Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen. *Yale Journal of Biology & Medicine* **71**: 355-65.

89. Donnelly DS, Zelterman D, Sharkis S, Krause DS. (1999). Functional activity of murine CD34+ and CD34− hematopoietic stem cell populations. *Experimental Hematology* **27**: 788–96.

Refereed Publications – Applications

90. Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu ML. (1999). Down regulation of $p27^{KIP1}$ and $Ki67/Mib1$ labeling index support the classification of thyroid carcinoma into prognostically relevant categories. *American Journal of Surgical Pathology* **23**: 678–85.

91. Jillella AP, Doria R, Khan K, Zelterman D, Ahmad YH, Smith BR, Holmes W, Becker P, Roberts KB, Rappeport JM. (1999). Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. *Bone Marrow Transplantation* **23**: 1095–100.

92. Seropian S, Nadkarni R, Jillella AP, Salloum E, Burtness B , Hu GL, Zelterman D, Cooper DL. (1999). Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: Out-patient treatment is a viable option. *Bone Marrow Transplantation* **23**: 599–605.

93. Salloum E, Tanoue LT, Wackers FJ, Zelterman D, Hu GL, Cooper DL. (1999). Assessment of cardiac and pulmonary function in adult patients with Hodgkin's disease treated with ABVD or MOPP/ABVD plus adjuvant low-dose mediastinal irradiation. *Cancer Investigation* **17**: 171–80.

94. Poo-Hwu W-J, Ariyan S, Lamb L, Zelterman D, Hu GL, Brown J, Fischer D, Buzaid A. (1999). Follow-up recommendations for American Joint Committee on Cancer Stages I–III malignant melanoma. *Cancer* **86**: 2252–8.

95. Leachman SA, Tigelaar RE, Shylankevich M, Slade MD, Irwin M, Chang E, Wu TC, Xiao W, Pazhani S, Zelterman D, Brandesma JL. (2000). GM-CSF priming plus papillomavirus E6 DNA vaccination: Effects on papilloma formation and regression in the CRPV-rabbit model. *Journal of Virology* **74**: 8700–8.

96. van Wattum, PJ, Chappell PB, Zelterman D, Scahill LD, Lecktman JF (2000). Patterns of response to acute Naxolone infusion in Tourette's Syndrome. *Movement Disorders* **15**: 1252–4.

97. Peng XY, Won JH, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth AB. (2001). The use of the L-Plastin promoter for adenoviral-mediated tumor-specific gene expression in ovarian and bladder cancer cell lines. *Cancer Research* **61**: 4405–13. UI: 11389068

Refereed Publications – Applications

98. Zhang W, Remenyik E, Zelterman D, Brash DE, Wikonkal NM. (2002). Escaping the stem cell compartment: Sustained UVB exposure allows *p53*-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. *Proceedings of the National Academy of Sciences* **98**: 13948–53. UI: 11707578

99. Forsyth BWC, Davis JA, Freudigman KA, Katz KH, Zelterman D (2002). Pregnancy and birth rates among HIV-infected women in the United States: The confounding effects of illicit drug use. *AIDS* **16**: 1–9. UI: 11834960

100. Chunikhovskiy SP, Zelterman D, van Hoff J (2002). Treatment of childhood acute lymphoblastic leukemia at a regional non-academic center in Belarus. *Medical and Pediatric Oncology* **39**: 202–6. UI: 12210452

101. Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL (2002). Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. *Journal of Virology* **76**: 7616–24. UI: 12097575

102. Bleickardt, E, Argris A, Rich R, Blum K, McKeon A, Tara H, Zelterman D, Burtness B, Davies MJ, Murren JR (2002). Phase I dose escalation trial of weekly Docetaxel plus Irinotecan in patients with advanced cancer. *Cancer Biology & Therapy* **1**: 646–51. UI: 12642688

103. Tangir J, Zelterman D, Ma J, Schwartz P. (2003). Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. *Obstetrics and Gynecology* **101**: 251–7. UI: 12576247

104. Shaywitz SE, Naftolin F, Zelterman D, Marchione KE, Holahan JM, Palter SF, Shaywitz BA (2003). Better oral reading and short term memory in midlife postmenopausal women taking estrogen. *Menopause* **10**: 420–6. UI: 14501603

105. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. (2003). An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dentritic cells. *Proceedings of the National Academy of Sciences* **100**: 15101–6. UI: 14645711

106. Zambrano E, El-Hennawy M, Ehrenkranz R, Zelterman D, Reyes-Mugica M (2004). Total prenatal nutrition induced liver pathology: An autopsy series of 24 newborn cases. *Pediatric and Developmental Pathology* **7**: 425–32. UI: 15547767

Refereed Publications – Applications

107. Psyrri A, Kwong M, DiStasio S, Lekakis L, Kassar M, Sasaki C, Wilson LD, Hafty BG, Son YH, Ross DA, Weinberger PM, Chung GG, Zelterman D, Burtness BA, Cooper DL (2004). Cisplatin, 5-fluorouracil, and leucovorin (PFL) induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: Long term follow-up. *Journal of Clinical Oncology* **22**: 3061–9. UI: 15284256

108. Williams A-L, Selwyn PA, Liberti L, Molde S, Njike VY, McCorkle R, Zelterman D, Katz DL (2005). A randomized controlled trial of meditation and massage effects on quality of life in people with late stage disease: A pilot study. *Journals of Palliative Medicine* **8**: 939–52. UI: 16238507 AN: 0081030

109. Abu-Khalaf MM, Windsor S., Ebisu K., Salikooti S, Ananthanarayanan G, Chung GG, Digiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burness BA. (2005). Five year update of an expanded phase II study of dose-dense and -intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in high risk breast cancer. *Oncology* **69**:372–83. UI: 16319508

110. Fontes ML, Mathew JP, Rinder HM, Zelterman D, Smith BR, Rinder CS, and the Multicenter Study of Perioperative Ischemia Research Group (2005). Aterial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. *Anesthesia and Analgesics* **101**: 17–23. UI: 15976199

111. Murren JR. Andersen N. Psyrri D. Brandt D. Nadkarni R. Rose M. Davies MJ. Parisot N. Rosenfield AT. Pizzorno G. Zelterman D. (2005). Evaluation of irinotecan plus paclitaxel in patients with advanced non-small cell lung cancer. *Cancer Biology & Therapy* **4**:1311–5. UI: 16258263

112. Moss RL, Dimmitt RA, Barnhart DC, Sylvester KG, Brown RL, Powell DM, Islam S, Langer JC, Sato TT, Brandt ML, Lee H, Blakely ML, Lazar EL, Hirschl RB, Kenney BD, Hackam DJ, Zelterman D, Silverman BL, (2006). Laparotomy compared with peritoneal drainage in infants with necrotizing enterocolitis and intestinal perforation. *New England Journal of Medicine* **354**: 2225–34. UI: 16723614

113. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. (2006). Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. *Journal of Clinical Oncology.* **24**: 2998-3006. UI: 16769986

Refereed Publications – Applications

114. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H. (2006). Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. *Cancer* **107**: 299–308. UI: 16773633

115. Shaywitz BA, Skudlarski P, Holohan JM, Marchione, KE, Constable RT, Fulbright RK, Zelterman D, Lacadie C, Shaywitz SE (2007). Age-related changes in reading systems of dsylexic children. *Annals of Neurology* **61**: 363–70. UI: 17444510

116. Brandsma JL Shylankevich M, Buonocore L, Su Y, Roberts A, Rose JK, Zelterman D. (2007). Vesicular stomatitis virus (VSV)-based therapeutic vaccination against the E1, E2, E6 and/or E7 proteins of cottontail rabbit papillomavirus (CRPV). *Journal of Virology*. **81**: 5749–58. UI: 17392369

117. Brandsma JL Shylankevich M, Buonocore L, Su Y, Roberts A, Rose JK, Zelterman D. (2007). Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. *Vaccine* **25**: 6158–63. UI: 17630050

118. Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasaio RB. (2007). Phase II study of capcitabine with concomitant radiotherapy for paients with locally advanced pancreatic cancer: Up–regulation of thymidine phosphorylase. *The Cancer Journal* **13**: 247–56. UI: 17762760

119. Abu-Khalaf MM, Juneja V, Chung GG, DiGiovanna MP, Sipples R, McGurk M, Zelterman D, Haffty B, Reiss M, Wackers FJ, Lee FA, Burtness BA. (2007). Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. *Breast Cancer Research & Treatment* **104**: 341–9. UI: 17051423

120. Gálvez JA, McCarthy SM, Weinreb J, Zelterman D, White RI, Pollak J, Tal MG (2008). Comparison of MRI outcomes of uterine artery embolization for uterine leiomyoma using tris-acryl gelatin microspheres, poly-vinyl alcohol spheres and poly-vinyl alcohol particles. *Journal of Computer Assisted Tomography* **32**: 356–61. UI: 18520537

121. McAlpine JN, Hodgson EJ, Abramowitz S, Richman SM, Su Y, Kelly MG, Luther M, Baker L, Zelterman D, Rutherford TJ, Schwartz PE. (2008). The incidence and risk factors associated with postoperative delirium in geriatric patients undergoing surgery for suspected gynecologic malignancies. *Gynecologic Oncology* **109**: 296–302 UI: 18374970.

Refereed Publications – Applications

122. Yu JB, Zelterman D, Decker RH., Knisely JP. (2008). Impact of immediate postoperative death on the estimation of a survival benefit from postoperative radiation therapy for cancer of the gallbladder. *Journal of Clinical Oncology*. **26**: 4523. UI: 18802172

123. Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. (2008). Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. *International Journal of Colorectal Disease*. **23**: 139–45. UI: 17909820

124. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. *Cancer Research* **68**: 8535–40 UI: 18922928

125. Brandsma JL, Sun Y, Lizardi PM, Tuck DP, Zelterman D, Haines GK, Martel M, Harigopal M, Schofield K, Neapolitano M. (2009). Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. *Virology* **389**: 100-107. UI: 19443004

126. Kim Y, Lin Q, Zelterman D, Yun Z. (2009). Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. *Cancer Research*. **69**: 9271–80. UI: 19934310

127. LaMotte RH, Shimada SG, Green BG, Zelterman D. (2009). Pruritic and nociceptive sensations and dysesthesias from a spicule of cowhage. *Journal of Neurophysiology* **101**: 1430–1443. UI: 19144738

128. Chae WJ, Gibson TF, Zelterman D, Hao L, Henegariu O, Bothwell AL. (2010). Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. *Proceedings of the National Academy of Sciences* **107**: 5540–4. UI: 20212110

129. McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. (2010). Metachronous primary melanoma and lymphoma. *Annals of Plastic Surgery* **64**: 229-32. UI: 20098111

130. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. (2010). *KRAS*-variant in ovarian cancer acts as a genetic marker of cancer risk. *Cancer Research*. **70(16)**:6509–15. UI: 20647319

Refereed Publications – Applications

131. Boffa DJ, Detterbeck FC, Smith EJ, Rami-Porta R, Crowley J, Zelterman D, Tanoue L, Kim AW, Goldstraw P. (2010). Should the 7th edition of the lung cancer stage classification system change treatment algorithms in non-small cell lung cancer? *J Thorac Oncol.* **5**(11):1779–83. PMID: 20975377

132. Kidane D, Jonason AS, Gorton TS, Mihaylov I, Pan J, Keeney S, de Rooij DG, Ashley T, Keh A, Liu Y, Banerjee U, Zelterman D, Sweasy JB. (2010). DNA polymerase beta is critical for mouse meiotic synapsis. *EMBO Journal* **29**: 410–23. PMID: 20019666

133. Booth CJ, Brooks MB, Rockwell S, Murphy JW, Rinder HM, Zelterman D, Paidas MJ, Compton SR, Parks P. (2010). WAG-F8$^{\mathrm{m1Ycb}}$ rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A. *Journal of Thrombosis and Haemostasis,* **8**: 2472–7. DOI: 10.1111/j.1538-7836.2010.03978.x PMID: 20626616

134. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. (2011). Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. *Cell Cycle.* **10**(1):90–9. PMID: 21191178

135. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. (2011). A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 2011 Apr;12(4):377-86. Epub 2011 Mar 22. Erratum in: *Lancet Oncol.* (2011) **12**(6):522. PMID: 21435948

136. Kidane D, Dalal S, Keh A, Liu Y, Zelterman D, Sweasy JB. (2011). DNA polymerase beta is critical for genomic stability of sperm cells. *DNA Repair (Amst).* **10**(4):390–7. PMID: 21333614

137. Williams-Fritze MJ, Smith PC, Zelterman D, Carlson-Scholz JA. (2011). Fructosamine reference ranges in Rhesus macaques *(Macaca mulatta). Journal of the American Association for Laboratory Animal Science* **50**(4) 462–5. PMID: 21838972

138. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A *KRAS* variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. (2012). *Oncogene* doi: 10.1038/onc.2011.539. PMID: 22139083

Refereed Publications – Applications

139. Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. (2012). Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. *PLoS One* **7**(3): e31786. doi:10.1371/journal.pone.0031786 PMID: 22412840

140. Niccolai LM, Julian PJ, Bilinski A, Mehta NR, Meek JI, Zelterman D, Hadler JL, Sosa L. (2012). Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. *American Journal of Public Health* PMID: 22515856

141. Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. (2012). Comparative risks of non-prescription analgesics: A structured topic review and research priorities. *Expert Opinion in Drug Safety* 2012 **11**: 33–44. PMID: 22010836.

142. Donigan KA, Sun KW, Nemec AA, Murphy DL, Cong X, Northrup V, Zelterman D, Sweasy JB. (2012). The human POLB gene is mutated in a high percentage of colorectal tumors. *Journal of Biological Chemistry* **287**: 23830–9. doi:10.1074/jbc.M111.324947 PMID: 22577134

143. Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. (2012). The KRAS-Variant is associated with risk of developing double primary breast and ovarian cancer. *PLoS One* **7**(5):e37891. PMID: 22662244

144. Lygizos M, Shenoi SV, Brooks RP, Bhushan A, Brust JCM, Zelterman D, Deng Y, Northrup V, Moll AP, Friedland GH. (2013). Natural ventilation reduces high TB transmission risk in traditional homes in rural KwaZulu-Natal, South Africa. *BMC Infectious Diseases* doi: 10.1186/1471-2334-13-300. PMID: 23815441

145. Senejani AG, Liu Y, Kidane D, Maher SE, Zeiss CJ, Park HJ, Kashgarian M, McNiff J, Zelterman D, Bothwell ALM, Sweasy JB. (2014). Mutation of POL β causes lupus in mice. *Cell Reports* **6**:1-8. doi: 10.1016/j.celrep.2013.12.017. PMID: 24388753.

146. Brandsma JL, Harigopal M, Kiviat NB, Sun Y, Deng Y, Zelterman D, Lizardi P, Shabanova V, Levi A, Yaping T, Hu X, and Qinghua Feng Q. (2014). Methylation of twelve CpGs in human papillomavirus type 16 (HPV16) as an informative biomarker for the triage of women positive for HPV16 infection. *Cancer Prevention Research* 2014 May;7(5):526–33. doi: 10.1158/1940-6207.CAPR-13-0354. Epub 2014 Feb 20. PMID: 24556390

Refereed Publications – Applications

147. Abu-Khalaf M, Baumgart M, Gettinger SN, Tuck D, Zelterman D, Doddamane I, Deshpande HA, DiGiovanna M, Azodi M, Schwartz PE, Harris L (2015). A Phase Ib study of the mammalian target of Rapamycin inhibitor Sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. *Cancer* **121(11)**:1817–26. doi: 10.1002/cncr.29254. PMID: 25649370

148. Acevedo-Gadea C , Hatzis C, Chung G , Fishbach N, Lezon-Geyda K, Zelterman D, DiGiovanna MP, Harris L, Abu-Khalaf MM (2015). Sirolimus and Trastuzumab combination therapy for HER2 positive metastatic breast cancer after progression on prior Trastuzumab therapy. *Breast Cancer and Research Treatment* **150**:157–67. doi: 10.1007/s10549-015-3292-8. PMID: 25687356

149. McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. (2015). Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. *Cell Cycle* **14**:2091–9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11. PMID: 25961464

150. Pine AB, Lee EJ, Sekeres M, Steensma DP, Zelterman D, Prebet T, DeZern A, Komrokji R, Litzow M, Luger S, Stone R, Erba HP, Garcia-Manero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. (2017). Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. *Transfusion.* **57**:289–95. doi: 10.1111/trf.13934.PMID: 27878822

151. Nemec AA, Abriola L, Merkel JS, de Stanchina E, DeVeaux M, Zelterman D, Glazer PM, Sweasy JB. (2017). DNA polymerase beta germline variant confers cellular response to cisplatin therapy. *Molecular Cancer Research* **15**:269–280. doi: 10.1158/1541-7786.MCR-16-0227-T. PMID: 28074003

152. Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, Gan G, Li F, Zelterman D, Boddupalli CS, Zhang L, Verma R, Ferencz TM, Dhodapkar MV. (2017). Clinical and serologic responses after a two-dose series of high-dose influenza vaccine in plasma cell disorders: A prospective, single-arm trial. *Clinical Lymphoma, Myeloma & Leukemia* S2152-2650:296–304 doi: 10.1016/j.clml.2017.02.025.

Refereed Publications – Applications

153. Goldberg SB, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zelterman D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA. (2018). Early assessment of lung cancer immunotherapy response via circulating tumor DNA. *Clinical Cancer Research* doi: 10.1158/1078-0432.CCR-17-1341. PMID: 29330207

154. Ray S, Breuer G, DeVeaux M, Zelterman D, Bindra R, Sweasy JB. (2018). DNA polymerase beta participates in DNA end-joining. *Nucleic Acids Research* **46**:242–255. doi: 10.1093/nar/gkx1147. PMID: 29161447

155. Gettinger SN, Wurtz A, Goldberg SB, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zelterman D, Politi K, Herbst RS. (2018). Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. *Journal of Thoracic Oncolcology* pii: S1556-0864(18)30210-7. doi: 10.1016/j.jtho.2018.03.008. PMID: 29578107

156. Gettinger S, Choi J, Mani N, Sanmamed M, Datar I, Sowell R, Du V, Kaftan E, Goldberg S, Dong W, Zelterman D, Politi K, Kavathas P, Kaech S, Yu X, Zhao H, Schlessinger J, Lifton R, Rimm D, Chen L, Herbst R, and Schalper K. (2018). A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. *Nature Communications* 9: 3196. doi: 10.1038/s41467-018-05032-8 PMCID: PMC6086912.

157. Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. (2018). Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. *Ann Hematol.* doi: 10.1007/s00277-018-3427-1. PMID: 30027436

158. Wong PF, Wei W, Smithy JW, Acs B, Toki MI, Blenman KR, Zelterman D, Kluger HM, Rimm DL. (2018). Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma. *Clin Cancer Res* **25**: 2442–2449 doi: 10.1158/1078-0432.CCR-18-2652.

159. Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. (2019). Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. *J Immunother Cancer* **7**:194 doi: 10.1186/s40425-019-0675-0

Refereed Publications – Applications

160. Rahimy E, Weidhaas J, Wei W, Lannin D, Horowitz N, Higgins S, Wilson LD, Knowlton C, Moran MS, Young MR, Killelea B, Chagpar A, Yeboa DN, Zelterman D, Evans S. (2019). Patient-reported outcomes and cosmesis in a feasibility study of 4-dimensional simulated image guided accelerated partial breast irradiation. *Pract Radiat Oncol.* 2019 Feb 20. pii: S1879-8500(19)30047-5. doi: 10.1016/j.prro.2019.01.013

161. Hastings K, Yu H, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, A. Wurtz A, Cai11 G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME,Ladanyi M, Zelterman D, R.S. Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. (2019). EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer. *Ann Oncol.* 2019 May 14. pii: mdz141. doi: 10.1093/annonc/mdz141

162. Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, Goldberg SB, Politi K. (2019). The EGFR exon 19 mutant L747-A750¿P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. *Clin Cancer Res.* pii: clincanres.0780.2019. doi: 10.1158/1078-0432.CCR-19-0780.

163. Ayeni D, Miller B, Kuhlmann A, Ho PC, Robles-Oteiza C, Gaefele M, Levy S, de Miguel FJ, Perry C, Guan T, Krystal G, Lockwood W, Zelterman D, Homer R, Liu Z, Kaech S, Politi K (2019). Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors. *J Immunother Cancer* **7**:172. doi: 10.1186/s40425-019-0643-8

164. Wong PF, Wei W, Gupta S, Smithy JW, Zelterman D, Kluger HM, Rimm DL. (2019). Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma. *J Immunother Cancer* **23**:194. doi: 10.1186/s40425-019-0675-0

165. Roberts J, Brandow A, Devine L, Zelterman D, Hendrickson J (2020). Daily cannabis users with sickle cell disease show fewer admissions than others with similar pain complaints. *Cannabis and Cannabinoid Research* doi: 10.1089/can.2019.0036

Refereed Publications – Applications

166. Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Shanwetter Levit N, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. (2021). A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1 *Clinical Cancer Research* doi: 10.1158/1078-0432.CCR-21-0903.

167. Chang E-S, Monin JK, Zelterman D, Levy BR (2021). Impact of structural ageism on greater violence against older persons: a cross-national study of 56 countries. *BMJ Open* doi: 10.1136/bmjopen-2020-042580.

168. LoRusso PM, Sekulic A, Sosman JA, Liang WS, Carpten J, Craig DW, Solit DB, Bryce AH, Kiefer JA, Aldrich J, Nasser S, Halperin R, Byron SA, Pilat MJ, Boerner SA, Durecki D, Hendricks WPD, Enriquez D, Izatt T, Keats J, Legendre C, Markovic SN, Weise A, Naveed F, Schmidt J, Basu GD, Sekar S, Adkins J, Tassone E, Sivaprakasam K, Zismann V, Calvert VS, Petricoin EF, Fecher LA, Lao C, Eder JP, Vogelzang NJ, Perlmutter J, Gorman M, Manica B, Fox L, Schork N, Zelterman D, DeVeaux M, Joseph RW, Cowey CL, Trent JM. (2021). Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. *PLoS One* **16**:e0248097. doi: 10.1371/journal.pone.0248097. PMID: 33826614

169. Chang E-S, Monin J, Zelterman D, Levy B (2021). Impact of structural ageism on greater violence against older persons: A cross-national study of 56 countries *Innov Aging* **5**(Suppl 1): 179 doi: 10.1093/geroni/igab046.683

170. Chang E-S, Monin J, Zelterman D, Levy B (2021). Structural and individual ageism predicts elder abuse proclivity and perpetration. *Innov Aging* **5**(Suppl 1):88–89. doi: 10.1093/geroni/igab046.338

171. Chang E-S, Monin J, Zelterman D, Isenberg N, Levy B (2021). Dehumanization of older family members: Novel determinants of elder abuse proclivity by caregivers. *Innov Aging* **5**(Suppl 1):320–321. doi: 10.1093/geroni/igab046.1250

172. Abu-Khalaf MM, Alex Hodge K, Hatzis C, Baldelli E, El Gazzah E, Valdes F, Sikov WM, Mita MM, Denduluri N, Murphy R, Zelterman D, Liotta L, Dunetz B, Dunetz R, Petricoin EF, Pierobon M. AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers. *NPJ Precis Oncol* 2023 Feb 16;7(1):18. doi: 10.1038/s41698-023-00360-5. PMID: 36797347; PMCID: PMC9935518.

Refereed Publications – Applications

173. Chang ES, Monin JK, Isenberg N, Zelterman D, Levy BR. Implicit and Explicit Dehumanization of Older Family Members: Novel Determinants of Elder Abuse Proclivity. *Stigma Health.* 2023 Feb;8(1):40-48. doi: 10.1037/sah0000370. Epub 2022 Mar 17. PMID: 37092028; PMCID: PMC10120856.

174. Cecchini M, Salem RR, Marie Robert M, Czerniak S, ..., Lacy J (2024). Perioperative modified FOLFIRINOX for resectable pancreatic cancer. A nonrandomized controlled trial. *JAMAOncology* doi:10.1001/jamaoncol.2024.1575

175. Calix R, Wilson JH, Mueller M, Glazer PM, Zelterman D, Deveaux M, Zeiss C, Jayakumar AR, Barnea ER, Paidas MJ (2026). Synthetic preimplantation factor (sPIF) improves survival and GI function in acute lethal radiation syndrome in a clinically relevant murine model. *International Journal of Molecular Sciences*

Book Chapters and Conference Proceedings

1. Youn TIK and Zelterman D. (1988). "Institutional career mobility in academia." In: *Academic Labor Markets and Careers*, D.W. Breneman and T.I.K. Youn, editors. Falmer Press, New York (pp. 52–73).

2. Zelterman D and Balakrishnan N. (1992). "Univariate generalized distributions" In: *Handbook of the Logistic Distribution*, N. Balakrishnan, editor. Marcel Dekker, New York. (pp. 209–222).

3. Zelterman D and Louis TA. (1992). "Contingency tables in medical studies" In: *Medical Uses of Statistics*, 2nd edition, J.C. Bailer III and F. Mosteller, editors. NEJM Books, Boston, Mass. (pp. 293– 310).

4. Zelterman D and Lindgren T. (1992). "Bootstrap methods for extreme order statistics." *Computing Science and Statistics: INTERFACE '90 Proceedings*, C. Page and R. LePage, editors. Springer Verlag, New York. (pp. 580–582).

5. Louis TA and Zelterman D. (1994). "Bayesian approaches to research synthesis" *The Handbook of Research Synthesis*, H. Cooper and L. Hedges, editors Russell Sage Foundation, New York. (pp. 411–422).

6. Strawderman RL and Zelterman D. (1998). "A semiparametric bootstrap for simulating extreme order statistics" *Handbook of Statistics:* Volume 16, *Order Statistics and Their Applications.* C.R. Rao and N. Balakrishnan, editors. Amsterdam: North-Holland (pp. 441–462).

7. Zelterman D. (1998). "The multinomial distribution" *Encyclopedia of Biostatistics.* J. Wiley, New York.

8. Zelterman D and Yu C. (1999). "Multivariate discrete models for longevity in twins" *Diagnosis and Prediction.* S. Geisser, editor. New York: Springer–Verlag. (pp. 131–140).

9. Zelterman D and Lin H. (2004). "Diagnostics for the accelerated life time model of survival data" *Handbook of Statistics*, Vol 24: *Survival Analysis.* C.R. Rao and N. Balakrishnan, editors. Amsterdam: North-Holland. (pp. 443–59).

10. Moss R, Dimmitt RA, Barnhart DC, Zelterman D, Silverman BL (2023). "Laparotomy versus peritoneal drainage for necrotizing enterocolitis and perforation" In: *50 Landmark Papers every Pediatric Surgeon Should Know*, Davenport M, Aldeiri B, Davidson J, eds. doi: 10.1201/b23252-18

Book Chapters and Conference Proceedings

11. Zhou, N, Blaha, O, Zelterman D (2024). "Distributions and Their Approximations for p-Values" In: *Biostatistics in Biopharmaceutical Research and Development*, Chen D-G, editor doi: 10.1007/978-3-031-65937-9_16.

Reviews and Letters

1. Zelterman D. (1984). Review of E. Tufte: *The Visual Display of Quantitative Information. Journal of the American Statistical Association* **79**: 469.

2. Zelterman D. (1985). Review of C.C. Li: *Analysis of Unbalanced Data: a Pre-Program Introduction. Journal of the American Statistical Association* **80**: 790.

3. Zelterman D. (1986). Review of N. Holmes: *Designer's Guide to Creating Charts and Diagrams. Journal of the American Statistical Association* **81**: 875.

4. Zelterman D. (1986). The relationship between benchmark tests and microcomputer price. *Communications of the ACM* **29**: 1240 (letter).

5. Rollings RC, Garrard J, Kane RL, Makris L, Dunham T, Heston LL, Cooper S, Ratner ER, and Zelterman D. (1991). Is bias inherent in HCFA-sponsored research? *Journal of the American Medical Association* **266**: 63–4.

6. Kushi LH, Zelterman D, Jacobs DR, and Potter JD (1992). The impact of dietary measurement error on planning sample size required in a cohort study. *American Journal of Epidemiology* **134**: 1470–2 (letter).

7. Zelterman D. (1994). Review of R.D. Retherford and M.K. Choe: *Statistical Models for Causal Analysis. Technometrics* **36**: 327–8.

8. Zelterman D. (1995). Referee deadlines. *Amstat News* **223**: 22 (letter).

9. Zelterman D. (2000). Review of K. Lange: *Numerical Analysis for Statisticians. Technometrics.*

10. Zelterman D. (2000). Review of J. Pearl: *Causality. Technometrics.*

11. Lin H and Zelterman D. (2001). Review of T.M. Therneau and P.M. Grambsch: *Modeling Survival Data. Technometrics.*

12. Zelterman D. (2004). Review of K.B. Korb and A.E. Nicholson: *Bayesian Artificial Intelligence. Technometrics.*

13. Lally BE, Zelterman D, Colasanto J, Haffty BG, Detterbeck FC, Wilson LD. (2006). Postoperative chemotherapy for N2 non-small-cell lung cancer: Conclusions are not black and white, but gray. *Journal of Clinical Oncology* **24**: 5612–3.

14. Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. (2007). Since chemotherapy is now the standard in node-positive lung cancer, what is the role of postoperative radiotherapy? *Journal of Clinical Oncology* **25**: 460–1.

Ph.D. Dissertations Directed

1. S.-F. Chan, "Analysis of high dimensional categorical data." (1995). University of Minnesota.

2. A. Sengupta, "Models and analysis for longitudinal binary data." (1996). University of Minnesota.

3. G.L. Hu, "Changepoint survival models applied to kidney transplant time to organ rejection." (1998). Yale University.

4. C. Yu, "Discrete distributions for use in familial disease clusters." (1998). Yale University. Winner of a 1996 ENAR Student Travel Award.

5. Y. Li, "Methods for multiply matched case control studies with different classes of controls." (2003). Yale University. Winner of a 2003 ENAR Student Travel Award.

6. J. Li, "Rank tests for paired, exchangeable survival data." (2004). Yale University. Winner of a 2001 ENAR Student Travel Award.

7. M. DeVeaux, "Phase II designs for cancer clinical trials." (2018).

